| The causal relationship between immune cells mediating FIT3L, CCL4, OSM, and skin-derived deteriorated tumors. | The causal relationship between immune cells mediating FIT3L, CCL4, OSM, and skin-derived deteriorated tumors.
Gong W, Zhou J, Hou Y, Zhang J, He P, Yu Q., Free PMC Article | 07/26/2024 |
| Exercise-induced crosstalk between immune cells and adipocytes in humans: Role of oncostatin-M. | Exercise-induced crosstalk between immune cells and adipocytes in humans: Role of oncostatin-M.
Dollet L, Lundell LS, Chibalin AV, Pendergrast LA, Pillon NJ, Lansbury EL, Elmastas M, Frendo-Cumbo S, Jalkanen J, de Castro Barbosa T, Cervone DT, Caidahl K, Dmytriyeva O, Deshmukh AS, Barrès R, Rydén M, Wallberg-Henriksson H, Zierath JR, Krook A., Free PMC Article | 01/30/2024 |
| Oncostatin M for characterizing the inflammatory burden and outcome of V-V ECMO in ARDS patients. | Oncostatin M for characterizing the inflammatory burden and outcome of V-V ECMO in ARDS patients.
Setiadi H, El-Banayosy AM, Long JW, Maybauer MO, Mihu MR, El Banayosy A. | 12/20/2023 |
| Oncostatin M suppresses IL31RA expression in dorsal root ganglia and interleukin-31-induced itching. | Oncostatin M suppresses IL31RA expression in dorsal root ganglia and interleukin-31-induced itching.
Suehiro M, Numata T, Saito R, Yanagida N, Ishikawa C, Uchida K, Kawaguchi T, Yanase Y, Ishiuji Y, McGrath J, Tanaka A., Free PMC Article | 12/5/2023 |
| Role of oncostatin-M in ECM remodeling and plaque vulnerability. | Role of oncostatin-M in ECM remodeling and plaque vulnerability.
Patel P, Rai V, Agrawal DK., Free PMC Article | 11/16/2023 |
| Pancreatic Stromal Cell-derived Oncostatin M Confers Drug Resistance to a Multi-tyrosine Kinase Inhibitor in Pancreatic Cancer Cells. | Pancreatic Stromal Cell-derived Oncostatin M Confers Drug Resistance to a Multi-tyrosine Kinase Inhibitor in Pancreatic Cancer Cells.
Tatsuda D, Yoshida J, Ohishi T, Kawada M. | 06/2/2023 |
| Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polyps. | Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polyps.
Wang BF, Cao PP, Norton JE, Poposki JA, Klingler AI, Suh LA, Carter R, Huang JH, Bai J, Stevens WW, Tan BK, Peters AT, Grammer LC, Conley DB, Welch KC, Liu Z, Kern RC, Kato A, Schleimer RP., Free PMC Article | 05/11/2023 |
| Oncostatin M Contributes to Airway Epithelial Cell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps. | Oncostatin M Contributes to Airway Epithelial Cell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps.
Carsuzaa F, Bequignon E, Bartier S, Coste A, Dufour X, Bainaud M, Lecron JC, Louis B, Tringali S, Favot L, Fieux M., Free PMC Article | 04/15/2023 |
| Exogenous Oncostatin M induces Cardiac Dysfunction, Musculoskeletal Atrophy, and Fibrosis. | Exogenous Oncostatin M induces Cardiac Dysfunction, Musculoskeletal Atrophy, and Fibrosis.
Jengelley DHA, Wang M, Narasimhan A, Rupert JE, Young AR, Zhong X, Horan DJ, Robling AG, Koniaris LG, Zimmers TA., Free PMC Article | 10/1/2022 |
| Oncostatin M Improves Cutaneous Wound Re-Epithelialization and Is Deficient under Diabetic Conditions. | Oncostatin M Improves Cutaneous Wound Re-Epithelialization and Is Deficient under Diabetic Conditions.
Das A, Madeshiya AK, Biswas N, Ghosh N, Gorain M, Rawat A, Mahajan SP, Khanna S, Sen CK, Roy S., Free PMC Article | 05/14/2022 |
| The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure. | The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure.
Kubin T, Gajawada P, Bramlage P, Hein S, Berge B, Cetinkaya A, Burger H, Schönburg M, Schaper W, Choi YH, Richter M., Free PMC Article | 04/16/2022 |
| Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. | Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
Di Maira G, Foglia B, Napione L, Turato C, Maggiora M, Sutti S, Novo E, Alvaro M, Autelli R, Colombatto S, Bussolino F, Carucci P, Gaia S, Rosso C, Biasiolo A, Pontisso P, Bugianesi E, Albano E, Marra F, Parola M, Cannito S., Free PMC Article | 04/16/2022 |
| Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma. | Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma.
Headland SE, Dengler HS, Xu D, Teng G, Everett C, Ratsimandresy RA, Yan D, Kang J, Ganeshan K, Nazarova EV, Gierke S, Wedeles CJ, Guidi R, DePianto DJ, Morshead KB, Huynh A, Mills J, Flanagan S, Hambro S, Nunez V, Klementowicz JE, Shi Y, Wang J, Bevers J 3rd, Ramirez-Carrozzi V, Pappu R, Abbas A, Vander Heiden J, Choy DF, Yadav R, Modrusan Z, Panettieri RA Jr, Koziol-White C, Jester WF Jr, Jenkins BJ, Cao Y, Clarke C, Austin C, Lafkas D, Xu M, Wolters PJ, Arron JR, West NR, Wilson MS. | 04/16/2022 |
| Oncostatin M suppresses browning of white adipocytes via gp130-STAT3 signaling. | Oncostatin M suppresses browning of white adipocytes via gp130-STAT3 signaling.
van Krieken PP, Odermatt TS, Borsigova M, Blüher M, Wueest S, Konrad D., Free PMC Article | 03/26/2022 |
| Oncostatin M sensitizes keratinocytes to UVB-induced inflammation via GSDME-mediated pyroptosis. | Oncostatin M sensitizes keratinocytes to UVB-induced inflammation via GSDME-mediated pyroptosis.
Liu J, Zhong Y, Liu H, Yang H, Lu P, Shi Y, Wang X, Zheng W, Yu X, Xu Y, Yang B. | 02/26/2022 |
| Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. | Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis.
Lee BY, Hogg EKJ, Below CR, Kononov A, Blanco-Gomez A, Heider F, Xu J, Hutton C, Zhang X, Scheidt T, Beattie K, Lamarca A, McNamara M, Valle JW, Jørgensen C., Free PMC Article | 01/15/2022 |
| Endothelial Reprogramming Stimulated by Oncostatin M Promotes Inflammation and Tumorigenesis in VHL-Deficient Kidney Tissue. | Endothelial Reprogramming Stimulated by Oncostatin M Promotes Inflammation and Tumorigenesis in VHL-Deficient Kidney Tissue.
Nguyen-Tran HH, Nguyen TN, Chen CY, Hsu T., Free PMC Article | 01/8/2022 |
| Oncostatin M promotes hepatic progenitor cell activation and hepatocarcinogenesis via macrophage-derived tumor necrosis factor-alpha. | Oncostatin M promotes hepatic progenitor cell activation and hepatocarcinogenesis via macrophage-derived tumor necrosis factor-α.
Yang X, Shao C, Duan L, Hou X, Huang Y, Gao L, Zong C, Liu W, Jiang J, Ye F, Shi J, Zhao Q, Wu D, Wei L. | 01/8/2022 |
| Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment. | Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
Dinca SC, Greiner D, Weidenfeld K, Bond L, Barkan D, Jorcyk CL., Free PMC Article | 01/1/2022 |
| Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. | Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.
Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, Ferrante M, Cleynen I, De Hertogh G, Vermeire S., Free PMC Article | 12/25/2021 |
| Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort. | Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort.
Ezirike Ladipo J, He Z, Chikwava K, Robbins K, Beri J, Molle-Rios Z. | 10/30/2021 |
| Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways. | Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways.
Wang H, Lei L, Hu J, Li Y. | 10/2/2021 |
| TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGFbeta signaling in gastroenteropancreatic neuroendocrine neoplasms. | TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGFβ signaling in gastroenteropancreatic neuroendocrine neoplasms.
Xue J, Bai J, Long Q, Wei Y, Pan J, Li X, Tang Q., Free PMC Article | 07/24/2021 |
| Association of serum regenerating islet-derived protein 3-beta and oncostatin-M levels with the risk of acute coronary syndrome in patients with type 2 diabetes mellitus - A pilot study. | Association of serum regenerating islet-derived protein 3-beta and oncostatin-M levels with the risk of acute coronary syndrome in patients with type 2 diabetes mellitus - A pilot study.
K M, Adole PS, Vinod KV, Balamurugan N. | 07/10/2021 |
| Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis. | Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis.
Tsui FWL, Lin A, Sari I, Zhang Z, Tsui HW, Inman RD., Free PMC Article | 07/10/2021 |